Compare Amgen, Inc. (AMGN) vs United States Brent Oil Fund LP (BNO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs United States Brent Oil Fund LP — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while United States Brent Oil Fund LP trades at $43.58. The key difference: Amgen, Inc. pays a 2.77% dividend while United States Brent Oil Fund LP pays none, and Amgen, Inc. is trading nearer its 52-week high, United States Brent Oil Fund LP nearer its low. Which is the better fit depends on your goals.
| AMGN | BNO | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Commodities - Energy |
52-Week High | $388.16 | $60.13 |
52-Week Low | $271.18 | $27.20 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
BNO trades at $42.15, showing minimal daily movement with a slight 0.05% decline. Technical indicators present a neutral to bearish picture with mixed signals from moving averages and oscillators. Recent news highlights oil price volatility driven by Middle East tensions, with WTI crude experiencing significant swings. The stock currently trades near its pivot point of $42, with immediate support at $42 and resistance at $43.
The outlook remains cautious as geopolitical risks and oil market volatility create uncertainty. While strategic oil reserve buying through 2028 may provide demand support, concerns about China's oil demand recovery and potential market surpluses present headwinds. The neutral technical stance suggests waiting for clearer directional momentum before establishing significant positions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About United States Brent Oil Fund LP
BNO is a commodity ETF that tracks the daily price of Brent crude oil futures. It provides exposure to the international oil benchmark, which often trades at a premium to the U.S. WTI benchmark, and is primarily used for short-term trading due to roll costs.
Read more on BNO →
